Besides receptor overexpression, cancer cells also exhibit a striking deregulation between the spatial distribution, interaction, and signaling strength of membrane receptors, including EGFR [14] and HER2 [15,16,17,18], which correlates with an increased risk of resistance against targeted therapeutics [19]. This evidence concerns the gene ERBB2 and cancer.